Citigroup’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-383,486
| Closed | -$575K | – | 5851 |
|
|
2023
Q1 | $575K | Sell |
383,486
-89,998
| -19% | -$121K | ﹤0.01% | 3022 |
|
|
2022
Q4 | $473K | Buy |
473,484
+473,025
| +103,056% | +$638K | ﹤0.01% | 3216 |
|
|
2022
Q3 | $1K | Sell |
459
-576
| -56% | -$1.67K | ﹤0.01% | 5740 |
|
|
2022
Q2 | $3K | Sell |
1,035
-1,107
| -52% | -$2.73K | ﹤0.01% | 5831 |
|
|
2022
Q1 | $6K | Sell |
2,142
-6,734
| -76% | -$21.2K | ﹤0.01% | 5782 |
|
|
2021
Q4 | $41K | Sell |
8,876
-41,147
| -82% | -$257K | ﹤0.01% | 5166 |
|
|
2021
Q3 | $426K | Sell |
50,023
-111,123
| -69% | -$1.57M | ﹤0.01% | 3718 |
|
|
2021
Q2 | $2.64M | Buy |
161,146
+7,504
| +5% | +$152K | ﹤0.01% | 2437 |
|
|
2021
Q1 | $3.39M | Buy |
153,642
+141,700
| +1,187% | +$3.86M | ﹤0.01% | 2104 |
|
|
2020
Q4 | $369K | Buy |
11,942
+10,134
| +561% | +$256K | ﹤0.01% | 4478 |
|
|
2020
Q3 | $37K | Sell |
1,808
-1,220
| -40% | -$21.4K | ﹤0.01% | 5790 |
|
|
2020
Q2 | $47K | Sell |
3,028
-3,032
| -50% | -$35K | ﹤0.01% | 6061 |
|
|
2020
Q1 | $47K | Buy |
6,060
+3,011
| +99% | +$36.9K | ﹤0.01% | 6025 |
|
|
2019
Q4 | $44K | Buy |
3,049
+2,331
| +325% | +$36K | ﹤0.01% | 6418 |
|
|
2019
Q3 | $10K | Buy |
718
+260
| +57% | +$4.05K | ﹤0.01% | 7095 |
|
|
2019
Q2 | $7K | Sell |
458
-1,787
| -80% | -$28.5K | ﹤0.01% | 7409 |
|
|
2019
Q1 | $39K | Buy |
+2,245
| New | +$39.8K | ﹤0.01% | 6543 |
|
Citigroup's TCRR Position: Q2 2023 in Review
Citigroup sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 383,486 shares — an estimated $575K sold.
Citigroup first reported a position in TCRR in Q1 2019 and held it in 17 quarters. The position peaked at $3.39M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Citigroup reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Citigroup sold 383,486 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $575K.
- Citigroup first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 17 quarters.
- Citigroup's TCR2 Therapeutics Inc. Common Stock position peaked at $3.39M in Q1 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Citigroup's 13F filing for Q2 2023, filed 10 Aug 2023.